Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978846 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL3037239 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15721245 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8523079 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL16547556 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15265730 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959424 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969695 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4604138 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15264856 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733682-B1 | NOVEL ALLULOSE-DERIVED COMPOUND | CJ CHEILJEDANG CORP (KR) | 2024-04-10 | — | — | EP | claimed |
| EP-3733682-A1 | NOVEL ALLULOSE-DERIVED COMPOUND | Cj Cheiljedang Corporation (KR) | 2020-11-04 | — | — | EP | claimed |
| WO-2020189859-A1 | NOVEL ALLULOSE-DERIVED COMPOUND | 씨제이제일제당 (주) | 2020-09-24 | — | — | WO | claimed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | claimed |
| WO-2013178236-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2013-12-05 | — | — | WO | claimed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | claimed |
| EP-0673947-B1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | SANKYO CO (JP) | 2000-07-12 | — | — | EP | claimed |
| EP-0673947-A1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | Sankyo Company Limited (JP) | 1995-09-27 | — | — | EP | claimed |
| US-20260062633-A1 | EMULSION | QUADRISE INTERNATIONAL LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-12543766-B2 | Composition for inhibiting HMF production comprising allulose disaccharide | CJ CHEILJEDANG CORPORATION (KR) | 2026-02-10 | — | — | US | disclosed |
| US-12421267-B2 | Composition for preparing allulose and method for preparing allulose by using same | CJ CHEILJEDANG CORPORATION (KR) | 2025-09-23 | — | — | US | disclosed |
| EP-4581107-A1 | EMULSION | Quadrise International Ltd (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-3733682-B1 | NOVEL ALLULOSE-DERIVED COMPOUND | CJ CHEILJEDANG CORP (KR) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024047354-A1 | EMULSION | QUADRISE INTERNATIONAL LIMITED (GB) | 2024-03-07 | — | — | WO | disclosed |
| EP-0673947-B1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | SANKYO CO (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0673947-B1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | SANKYO CO (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0673947-A4 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES. | SANKYO CO (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0673947-A1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | Sankyo Company Limited (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0673947-A1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | Sankyo Company Limited (JP) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013685-A1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | SANKYO CO., LTD. (JP) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062633-A1 | EMULSION | C5, PHOSPHO1, PFKFB1 | MEN1 3528/4885KMT2A 3776/4885PYGB 1180/4885 |
| US-12421267-B2 | Composition for preparing allulose and method for preparing allulose by using same | NOTUM, AGPS, SI | MEN1 2784/4885KMT2A 2816/4885PYGB 1002/4885 |
| US-12543766-B2 | Composition for inhibiting HMF production comprising allulose disaccharide | DERA, ALDOA, HSD17B14 | MEN1 2175/4885KMT2A 1020/4885PYGB 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.